期刊文献+

中西医结合治疗慢性肾盂肾炎疗效观察 被引量:4

Observation of Integrated Chinese and Western Medicine for Chronic Pyelonephritis
下载PDF
导出
摘要 目的:观察中西医结合治疗慢性肾盂肾炎的临床疗效。方法:将82例慢性肾盂肾炎患者随机分为2组,对照组采用常规西医治疗;观察组在对照组治疗基础上给予自拟肾通淋汤治疗。2周为1疗程,治疗3疗程。观察2组治疗后血尿氮素(BUN)、肌酐(SCr)、内生肌酐清除率(CCr)、尿微球蛋白(尿β-MG)、血微球蛋白(血β-MG)的变化情况。结果:总有效率观察组95.1%,对照组73.2%,2组比较,差异有统计学意义(P<0.01)。治疗后观察组BUN、SCr、血β-MG、尿β-MG水平低于对照组,CCr水平高于对照组,2组比较,差异有统计学意义(P<0.01)。结论:在西医常规治疗的基础上给予中药肾通淋汤治疗,临床疗效显著,保护肾功能。 Objective. To investigate the clinical efficacy of integrated Chinese and western medicine in the treatment of chronic pyelonephritis. Methods: Eighty-two cases with chronic pyelonephritis were divided into the control group and the observation group. The patients in the control group were given conventional western medicine treatment, and patients in the observation group were treated with self-purposed Shen tonglin tag on the basis of the treatment of the control group. The treatment covered 3 courses lasting 6 weeks. The efficacy and changes in blood urea nitrogen (BUN), serum creatinine(SCr)and urine β2 micro-globulin(β2-MG) and other indicators were compared after treatment. Result: The total effective rate was 95.1% in the observation group, and was 73.2% in the control group, the difference being significant (P 〈 0.05). The levels of BUN, SCr, blood β-MG, urine β-MG and CCr in the observation group after treatment were obviously better than those in the control group(P 〈 0.05). Conclusion. integrated Chinese and western medicine is capable of significantly improving the effect and protecting renal function.
作者 俞强
机构地区 宁波市第一医院
出处 《新中医》 CAS 2015年第11期85-87,共3页 New Chinese Medicine
关键词 慢性肾盂肾炎 肾通淋汤 临床效果 Chronic Pyelonephritis,, Shen tonglin tang Clinical efficacy
  • 相关文献

参考文献5

二级参考文献16

  • 1吕永曼,易艳,黄晓丽,邵菊芳.雌激素对单侧输尿管梗阻大鼠肾间质纤维化的保护作用[J].中华肾脏病杂志,2006,22(6):348-352. 被引量:7
  • 2赵长安,王淑秀,许娜.肾脏雌激素受体亚型表达分布及补肾中药防治肾损害的受体机制[J].中国临床康复,2006,10(35):66-68. 被引量:6
  • 3Kang DH,Yu ES,Yoon KI,et al.The impact of gender on progression of renal disease:potential role of estrogen-mediated vascular endothelial growth factor regulation and vasclar protection.Am J Pathol,2004,164(2):679-688.
  • 4Stringer KD,Komers R,Osman SA,et al.Gender hormones and the progression of experimental polycystic kidney disease.Kidney Int,2005,68(4):1729-1739.
  • 5Mankhey RW,Bhatti F,Maric C.17beta-Estradiol replacemeat improves renal function and pathokgy associated with diabetic nephropathy.Am J Physiol Renal Physiol,2005,288(2):F399-F405.
  • 6Maric C,Sandberg K.Hinojosa-Laborde C.Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat.J Am Soc Nephrol,2004,15(6):1546-1556.
  • 7Birch Nielsen C,Krag S,Sterby R,et al.Transformming growth factor betal-induced glomerulopathy is prevented by 17beta-estradiol supplementation.Virchows Arch,2004,444(6):561-566.
  • 8Taylor AH,Al-Azzawi F.Immunolocalisation of estrogen receptor beta in human tissues.J Mol Endocrinol,2000,24(1):145-155.
  • 9国家食品药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2006.
  • 10张琪,张佩青,张琪.肾病医案精选[M].北京:科学出版社,2008:167-169.

共引文献18

同被引文献30

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部